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Structured Abstract 
 
Study Design. A study examining the clinical protocol of scoliosis wound irrigation, 
demonstrating Povidone-Iodine’s (PVI) effect on human osteoblast cells.   Primary 
and immortal cell line osteoblasts were treated with 0.35% PVI for 3 minutes, and 
analyzed for proliferation rate, oxidative capacity and mineralisation.  
Objective.  To model spinal wound irrigation with dilute PVI in vitro, in order to 
investigate the effect of PVI on osteoblast proliferation, metabolism and bone 
mineralisation. 
Summary of Background Data.  Previously PVI irrigation has been proposed as a 
safe and effective practice to avoid bacterial growth following spinal surgery. 
However, recent evidence in multiple cell types suggests that PVI has a deleterious 
effect on cellular viability and cellular function.   
Methods.  Primary and immortal human osteoblast cells were exposed to either PBS 
control or with 0.35% PVI for 3 min.   Cellular proliferation was measured over the 
duration of 7 days by MTS assay.  Oxygen consumption rate (OCR), extracellular 
acidification rate (ECAR) and proton production rate (PPR) were analysed using a 
Seahorse XFe24 Bioanalyzer. Protein expression of the electron transport chain 
subunits CII-SDHB, CIII-UQRCR2 and CV-ATP5A were measured via Western 
blotting.  Mineralised bone nodules were stained with alizarin red. 
 
Results. Expressed as a percentage of normal osteoblast proliferation, osteoblasts 
exposed to 0.35% PVI exhibited a significant 24% decrease in proliferation after 24 
h.  This was a sustained response, resulting in a 72% decline in cellular proliferation 
at 1 week.  There was a significant reduction in OCR, ECAR, and PPR (p<0.05), in 
osteoblasts that had been exposed to 0.35% PVI for 3 min, coupled with a marked 
reduction in the protein expression of CII-SDHB. Osteoblasts exposed to 0.35% PVI 
exhibited reduced bone nodule mineralisation compared to control PBS exposed 
osteoblasts (p<0.01). 
 
Conclusion.   PVI has a rapid and detrimental effect on human osteoblast cellular 
proliferation, metabolic function, and bone nodule mineralisation. 
 
Key Words:  Povidone-Iodine, PVI, Osteoblasts, wound irrigation, Spinal Surgery, 
Bone Mineralization, Cellular Metabolism, Cell Viability, Cell Proliferation 
 
Level of Evidence:  N/A 
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Key Points 
 Acute exposure to dilute PVI markedly reduces human osteoblast proliferation. 
 There is a significant reduction in human osteoblast metabolic capacity (OCR, 
ECAR, and PPR) after exposure to 0.35% PVI for 3 min.   
 Human osteoblasts exposed to 0.35% PVI for 3 min exhibited a marked reduction 
in succinate dehydrogenase B (CII-SDHB) protein expression. 
 Osteoblasts exposed to 0.35% PVI exhibited reduced bone nodule 
mineralisation. 
 
Key Points (3-5 main points of the article)
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Mini Abstract 
This study modelled the effect of using PVI wound irrigation during spinal surgery on 
human osteoblast cells.   Osteoblasts treated with 0.35% PVI for 3 minutes exhibited 
a decrease in proliferation rate, a significant reduction in metabolic capacity, and 
reduced bone nodule mineralisation. 
Mini Abstract (50 words)
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Introduction 1 
Surgical wound infection is a serious complication following spinal surgery. Infection 2 
rates in spinal surgery vary hugely and are dependent on a plethora of factors 3 
including patient co-morbidities and type of surgery being performed. In particular 4 
deformity correction procedures, with long wounds, long operating times and medical 5 
co-morbidities; infection rates can be as high as 19%. Surgical site infections can 6 
progress to deep infection, incur multiple operations with increased healthcare costs 7 
and impaired patient outcomes (1-6). 8 
 9 
To reduce the risk of wound infections, many spinal surgeons are using intra-10 
operative antimicrobial wound irrigates (7). One such irrigate which has been 11 
advocated and utilised is dilute Povidone-Iodine (PVI) (8). However, there is a 12 
paucity of evidence supporting this off-label practice. Two clinical papers have 13 
previously described this as a safe and effective practice (8, 9) but there is evidence 14 
that PVI has a deleterious effect on cellular viability and cellular function. Studies 15 
across multiple cells types and tissues, including fibroblasts, keratinocytes, 16 
chondrocyte, immune cells and synovial tissue have now demonstrated that PVI has 17 
cytotoxic effects (10-13). 18 
 19 
The PVI wound irrigation technique, as described by Chang et al. (9), involves 20 
complete immersion of the wound for 3 minutes with a preparation of 0.35% of PVI 21 
(diluted from commercially available 10% PVI “Videne”), followed by copious 22 
irrigation with normal saline, prior to decortication and wound closure. 23 
 24 
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Two laboratory studies (one human, one animal) describe the effects of PVI on 25 
osteoblasts. Whilst results were heterogeneous, all described a toxic effect of PVI on 26 
the osteoblast (14, 15). 27 
 28 
From a spinal surgery perspective, there are no studies which have examined 29 
whether PVI at clinically advocated concentrations has deleterious effects on human 30 
osteoblast viability and function. Addressing this is imperative since osteoblast 31 
proliferative and metabolic activity, together with their ability to form bone and 32 
mineralise, is essential for the establishment of solid fusion post-surgery.  33 
 34 
The aim of this study was to model the clinical protocol in vitro, in order to investigate 35 
the effect of dilute PVI washout on osteoblast proliferation, metabolic function and 36 
osteoblast bone nodule formation and mineralisation.  37 
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METHODS 38 
3.1 Cell culture 39 
Primary human osteoblast cells were cultured in differentiation media (10% fetal calf 40 
serum (FCS), penicillin (100 units/ml), streptomycin (100µg/ml), L-glutamine (2mM), 41 
non-essential amino acids (1%, Invitrogen) and Amphotericin B (2.5 µg/ml), β-42 
glycerophosphate (2mM), Ascorbic acid (50µg/ml) and Dexamethasome (10nM)) 43 
entirely. The human osteoblast cell line hFOB 1.19 (ATCC® CRL-11372™) (ATCC, 44 
England, UK) was cultured in growth media (1:1 mixture of Ham's F12 Medium 45 
Dulbecco's Modified Eagle's Medium, with 2.5 mM L-glutamine (without phenol red), 46 
10% fetal bovine serum (FBS), and 0.3mg/ml G418 prior to differentiation media. 47 
 48 
3.2 Preparation of primary human osteoblasts 49 
Ethical approval was granted by the United Kingdom (UK) National Research Ethics 50 
Service (National Health Authority, reference NRES 14-ES-1044), and institutionally 51 
approved and sponsored by the University of Birmingham as required under the UK 52 
Research Governance Framework. Study participants were provided in advance with 53 
a participant information sheet, and a participant consent form.  Following patient’s 54 
written consent, the femoral head was collected from a female patient (aged 62 55 
years) undergoing total joint replacement surgery for hip osteoarthritis.  The articular 56 
cartilage was removed from the femoral head and the subchondral bone cut into 57 
small chips. The bone chips were then washed thoroughly in serum-free primary 58 
osteoblast media to remove any excess blood, connective or adipose tissue and 59 
then incubated in differentiation media in a culture flask at 37°C (5% CO2). 60 
Differentiation media was replaced with fresh media 2x per week, and the bone chips 61 
removed upon the appearance of osteoblast cells.  62 
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 63 
3.3  Osteoblast proliferation assay 64 
Primary human osteoblasts and the human osteoblast cell line (hFOB 1.19) were 65 
plated at 6x103 cells per well in a 96 well plate. At confluency, the cells were 66 
incubated with either PBS control or with 0.35% PVI (diluted in PBS) for 3 minutes at 67 
room temperature. The wells were then aspirated, washed 5x with PBS and then 68 
placed back into osteoblast growth media. After 24, 48, 120, 144 and 168 h at 33°C, 69 
an MTS (Cell Titer Aqueous One Solution Cell Proliferation Assay, Promega) assay 70 
was performed as per manufacturer’s instructions as a measure of osteoblast 71 
proliferation.  72 
 73 
3.4  Osteoblast metabolic function 74 
Human osteoblast cells (hFOB 1.19) were plated at 6x103 cells per well in an XFe 24 75 
Cell Culture Microplate (Seahorse Bioscience, USA). At confluency, the cells were 76 
stimulated with 0.35% PVI diluted in PBS or with PBS control for 3min, thoroughly 77 
washed as described previously and placed back into growth media. After 24 h at 78 
33°C, XF Assay medium (XF base medium with 2mM GlutaMAX™) was then added 79 
to the plate and incubated at 33°C for 1 h.  80 
 81 
Using a XFe Extracellular Flux Analyzer (Seahorse Bioscience, USA) the oxygen 82 
consumption rate (OCR), extracellular acidification rate (ECAR) and proton 83 
production rate (PPR) of each well were measured simultaneously, in order to 84 
comprehensively profile the metabolic function of the osteoblasts. 85 
 86 
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3.5  Expression analysis of osteoblast mitochondrial oxidative phosphorylation 87 
components 88 
Human osteoblast cells (hFOB 1.19) cells were seeded at 6x104 cells per well in a 89 
24-well plate. Cells were stimulated with 0.35% dilute PVI or PBS control for 3min, 90 
and then washed in PBS as previously described before being cultured in growth 91 
media for 24 h (37°C, 5% CO2). Following 24 h, cells were washed in PBS and lysed 92 
in 1xLaemmli Sample Buffer (2%SDS, 5% 2-mercaptoethanol, 10% glycerol, 0.002% 93 
Bromophenol Blue, 0.0625M Tris HCL).  Equal amounts of total protein lysates were 94 
then applied to 12% SDS PAGE electrophoresis and blotted onto polyvinylidene 95 
difluoride (PVDF) membrane at 150V for 1 h. Blots were immunoprobed with an 96 
optimised antibody cocktail which contains antibodies to detect key components of 97 
mitochondrial oxidative phosphorylation, namely CII-SDHB 30kDa (ab14714), CIII-98 
UQCRC2 (ab14745) and CV-ATP5A (ab14748). Blots were developed using ECLTM 99 
Prime Western Blotting Detection Reagent Kit (GE Healthcare, UK) on the 100 
ChemiDocTM Imaging MP System (BIO-RAD, USA). 101 
 102 
3.7 Osteoblast bone nodule formation and mineralization assay 103 
Human osteoblast cells (hFOB 1.19) were seeded at 6x104 cells per well in a 24 well 104 
plate and treated with or without 0.35% PVI for 3 min as described previously, before 105 
being cultured in differentiation media. After 14 days, cells were stained with alizarin 106 
red solution in order to quantify the degree of mineralisation following the formation 107 
of bone nodules. Briefly, cells were incubated in alizarin red staining solution (0.5% 108 
Alizarin Red (Sigma-Aldrich, UK) in 1% ammonia solution at pH 4.5) for 10min at 109 
room temperature and washed with PBS to remove excess stain. Cells were then 110 
incubated in 10% cetyl pyridinium chloride (Sigma-Aldrich, UK) for 10 min at room 111 
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temperature. The supernatant was collected from each well and diluted 1:10 with the 112 
10% cetyl pyridinium chloride and read at OD550nm on a SpectraMAX Microplate 113 
Reader (Molecular Devices, USA). 114 
 115 
3.8 Statistical Analysis  116 
All statistical analyses were carried out using Prism5 (GraphPad Software Inc. 117 
California, USA). Unless otherwise stated, all data within figures represents Mean 118 
±SEM. MTS assay results were assessed by a one-way analysis of variance 119 
(ANOVA) with a Tukey Post Hoc. OCR, ECAR and PPR, and alizarin red analysis 120 
was compared using a Students un-paired t-test.   121 
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RESULTS 122 
3.1 Acute exposure to PVI markedly reduces osteoblast proliferation. 123 
Acute 3 min exposure of primary human osteoblasts to PVI at the clinical 124 
concentration of 0.35% significantly decreased cellular proliferation at 48, 120 and 125 
168 h post-exposure (Figure 1A). Expressed as a percentage of normal osteoblast 126 
proliferation (PBS control), osteoblasts exposed to 0.35% PVI exhibited a 24 ± 3.7% 127 
decrease in proliferation after 24 h (Figure 1B). This was a sustained response, 128 
which resulted in a 72% ± 2.3% decline in cellular proliferation at 1 week. The 129 
significant effect of PVI on cellular proliferation was also confirmed in the human 130 
osteoblast cell line (hFOB 1.19) (Figure 1C & 1D), with a 26 ± 3% after 24 h, and a 131 
42% ± 7% decline in proliferation relative to control after 6 days post-exposure.  132 
 133 
3.2 Acute exposure of osteoblasts to dilute PVI ablates osteoblast basal 134 
metabolic function. 135 
Assessment of metabolic functional activity of osteoblasts (hFOB.1.19) 24 h post-136 
exposure to 0.35% PVI or PBS control showed a significant reduction in OCR 137 
(0.32±0.13 vs -0.05±0.12 pmol/min/µg), ECAR (0.10±0.07 vs 0.01±0.02 mpH/min/µg) 138 
and PPR (87.64±18.78 vs 3.33±7.24 pmol/min/µg) (Figure 2A-C) in osteoblasts that 139 
had been exposed to 0.35% PVI for 3 min.  140 
 141 
3.3 Acute exposure of human osteoblasts to PVI markedly reduces CIII-SDHB 142 
protein expression, a key component of oxidative phosphorylation. 143 
To identify if the effect of 0.35% PVI on osteoblast metabolic function was due to a 144 
deleterious effect on mitochondrial function we then assessed the protein expression 145 
of electron transport chain subunits (II, III and CV), involved in mitochondrial 146 
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oxidative phosphorylation.  Human osteoblasts exposed to 0.35% PVI for 3 min 147 
exhibited a marked reduction in protein expression of succinate dehydrogenase B 148 
(CII-SDHB), and a moderate reduction in the protein expression of cytochrome b-c1 149 
complex subunit 2 (CIII-UQCRC2), compared to PBS control exposed osteoblasts. 150 
The protein expression of CV-ATP5A remained unchanged (Figure 2D). 151 
 152 
3.4 Acute stimulation with PVI reduces osteoblast mineralization 153 
We next determined whether the deleterious effects of 0.35% PVI on osteoblast 154 
proliferation and metabolic functional activity impacted on the ability of osteoblasts to 155 
form bone nodules and mineralise. At confluency, osteoblasts were stimulated with 156 
0.35% PVI for 3 min, washed with PBS thoroughly and allowed to proliferate and 157 
differentiate for a further 2 weeks in differentiation media. Alizarin red stained 158 
mineralisation was quantified and showed that osteoblasts exposed to 0.35% PVI 159 
exhibited significantly reduced bone nodule mineralisation (0.28±0.05), compared to 160 
control PBS exposed osteoblasts (0.37±0.06) (Figure 3).  161 
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Discussion 162 
PVI is advocated for wound irrigation following spinal surgery (8, 9), despite recent 163 
reports of its cytotoxicity in multiple cell types (10-13). Our in vitro study 164 
demonstrates that dilute PVI has fundamental deleterious effects on human 165 
osteoblast cells and their innate ability to mineralise. 166 
 167 
Utilising primary human osteoblasts, we have demonstrated that acute exposure of 168 
osteoblasts to PVI for only 3 min, followed by thorough washing, is sufficient to 169 
profoundly inhibit cellular proliferation. Dilute PVI was found to significantly inhibit 170 
proliferation within the first 24 h following the 3 min exposure to PVI. However, 171 
perhaps of greater concern, our data also reveals that the negative effects on 172 
proliferation are fully sustained over a time-course of 7 days, resulting in a 72% 173 
inhibition of proliferation at this time point. This demonstrates that once exposed to 174 
dilute PVI the osteoblast cells do not recover their proliferative activity. Critically, we 175 
have also demonstrated that exposure to dilute PVI inhibits the innate functional 176 
ability of osteoblasts to form mineralised bone nodules.  177 
 178 
Our data suggests that exposure to dilute PVI inhibits human osteoblast proliferation 179 
and mineralisation by preventing normal osteoblast metabolic function, since both 180 
basal oxygen consumption rate (a measure of aerobic mitochondrial respiration; 181 
(16)) and extracellular acidification rate and proton production rate (a measure of 182 
glycolytic metabolism; (16)) were ablated within 24 h post-exposure to 3 min of dilute 183 
PVI.    184 
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With regard to previous studies which have reported the effect of PVI on the 186 
osteoblast, Kaysinger (1995) found that 5% Betadine (0.5% PVI) was toxic to 187 
chicken osteoblasts (15). It is of note that the first non-toxic concentration reported 188 
by Kaysinger was 5% Betadine (0.5% PVI). From their results it is therefore not 189 
possible to ascertain where between 0.05% and 0.5% the toxic effects of PVI are 190 
manifested (15). In the paper of Cheng et al. (8) the concentration of 0.5% PVI 191 
appears to have been interpreted as the lowest toxic concentration and hence 192 
guided their choice of 0.35% PVI for irrigation. We would argue that this was a 193 
fundamental misinterpretation of the report of Kaysinger et al. We have now 194 
confirmed that 0.35% PVI is indeed toxic to human osteoblasts. 195 
 196 
Cabral et al (2007) assessed PVI exposure in human alveolar bone. They found 10% 197 
and 5% PVI resulted in immediate cell death. 1% PVI resulted in rounding up and 198 
cellular detachment (implied cell death), and that cellular proliferation was reduced at 199 
concentrations of 0.5% PVI and higher. Cabral also reported a significant reduction 200 
in Alkaline Phosphatase (AP) production at 0.05% and 0.2% PVI (14), indicative of 201 
reduced mineralisation activity. Our findings are in agreement with this, since we 202 
also found that PVI reduced osteoblast proliferation and have demonstrated a 203 
significant reduction in the production of mineralised bone (as measured by Alizarin 204 
red staining) with 0.35% PVI.  205 
 206 
Infection rates in spinal surgery vary widely. For example, infection rate following 207 
anterior cervical surgery is low, at around 0.1%, but infection rates can be up to 19% 208 
in spinal deformity surgery (5, 17). Critically, the results of deep infection can be 209 
devastating and occasionally fatal in patient groups with multiple co-morbidities. 210 
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Clearly therefore, efforts must be taken to reduce spinal infection. A very informative 211 
Best Practice Guideline in 2013 made a number of recommendations for the “high 212 
risk” spinal surgical patients. These included pre-operative washing with 213 
chlorhexidine, nutritional assessment, broad spectrum antibiotics and topical 214 
vancomycin powder. It is noteworthy that PVI irrigation was not among the 215 
recommendations (18).  216 
 217 
In 2005 and 2006 two reports from the same centre described the utilization of 218 
0.35% PVI lavage in spinal surgery (8, 9), and reported a clinically significant 219 
reduction in infection rates from 2.9% without PVI lavage, to 0.5% with PVI lavage. 220 
Clearly this is a commendable reduction in infection rates apparently attributable to 221 
the PVI lavage. However, the goal of many spinal surgeries is the establishment of 222 
solid bony fusion (union). Therefore, the potential negative effect of a given irrigate 223 
on bone union must be considered alongside any positive benefit on spinal infection 224 
rates.  225 
 226 
Measurement of union (and non-union) are difficult to comprehensively determine 227 
using Computed Tomography (CT) (Carreon et al. 2008). The only reliable method is 228 
surgical exploration. In lumbar fusion surgery non-union rates are reported to be 10-229 
20%. In fusions of 4-levels or more, and in particular in adult degenerative scoliosis 230 
the rate of non-union can be as high as 20- 60% (9, 19-21). 231 
 232 
Our study identifies a potential pathway for impaired bony union following PVI lavage 233 
in the clinical setting. The two reports from Cheng et al. (8) clearly state that on 234 
radiographic analysis there was no adverse effect on fusion rates. However, it is 235 
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noteworthy that the patients in these studies were overwhelmingly 2-level or fewer 236 
low-back fusions. These particular patients have a fairly predictable union rate of 237 
around 80-90%. It is possible therefore that the deleterious effect of PVI on the 238 
human osteoblast may have a greater clinical impact on longer fusions with higher 239 
inherent risks of non-union. Additionally Chang et al. (9) used plain X-ray for 240 
evaluation of bony fusion. This is not a reliable method for assessing bony fusion, 241 
with only 68% accuracy in lumbar spine fusions (22).  242 
 243 
Outside the scope of this report, but of importance to the surgeon considering using 244 
PVI for irrigation of surgical wounds are descriptions of systemic complications 245 
following iodine lavage. These include: significant systemic iodine absorption, acute 246 
thyroid dysfunction, cardiovascular collapse, renal failure and death. Whilst these are 247 
not immediately relevant to bone healing, it does suggest that iodine lavage is not a 248 
universally benign phenomenon (23-27). 249 
 250 
There are limitations to our study. It is not possible to replicate in vitro the entire 251 
biological system involved in bone healing. We cannot replicate or ascertain what the 252 
effect would be on the pluripotent stem cells that subsequently migrate to the site of 253 
bony healing after irrigation. We have only assessed the effect on one cell type (the 254 
osteoblast), we do not know what the effect of 0.35% PVI would be on other cell 255 
types involved in bone healing such as fibroblasts, osteoclasts and platelets. We 256 
also accept that although our primary osteoblasts were human, they were not 257 
isolated from spinal bone. It is therefore conceivable that osteoblasts within spinal 258 
bone could behave differently to osteoblasts from the appendicular skeleton. It is 259 
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reassuring however that our results are similar to those described by Kaysinger from 260 
chicken embryonic tibiae (15). 261 
 262 
In summary, we have demonstrated a clear deleterious effect of PVI to osteoblast 263 
proliferation and function and mineralisation. We suggest the advocated 264 
antimicrobial gains may be offset by the potential for impaired bone healing, 265 
particularly in long fusion procedures with higher non-union rates, where there is no 266 
clinical outcome data relating to PVI irrigation. 267 
 268 
Abbreviations 269 
 270 
PVI   Povidone-Iodine 271 
PBS   Phosphate buffered saline 272 
MTS 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-273 
sulfophenyl)-2H-tetrazolium, inner salt 274 
CII-SDHB  Succinate Dehydrogenase B 275 
CIII-UQCRC2 ubiquinol-cytochrome c reductase core protein II 276 
CV-ATP5A  ATP synthase 277 
 278 
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Figure Legends: 
 
Figure 1.  The effect of acute exposure to dilute PVI on the proliferation of primary 
human osteoblasts and a human osteoblast cell line.  A. Primary human osteoblasts 
stimulated with PBS and 0.35% PVI for 3 minutes prior to time dependent MTS 
assays.  ○ = PBS control; ● = 0.35% PVI stimulated (*p<0.05, ***p<0.001).  B. 
Percentage proliferation of primary osteoblasts when compared to PBS control 
stimulated osteoblasts (**p<0.01 between 24 and 120 h, §p<0.001 between 24 and 
168 h, †p<0.01 between 48 and 168 h). C. hFOB 1.19 cell proliferation as measured 
by MTS assay (*p<0.05, ***p<0.001).  D. Percentage proliferation of hFOB 1.19 
osteoblasts when compared to PBS control stimulated osteoblasts (*p<0.05; n=3). 
 
 
Figure 2. Metabolic activity of stable osteoblast culture following acute PVI 
stimulation. A. Oxygen consumption rate (OCR) of osteoblasts. B. Extracellular 
acidification rate of osteoblasts. C. Proton production rate of osteoblasts (Figure 2A-
C n=4, *=p<0.05). D. Western blot of cells stimulated with 0.35% PVI or PBS control 
24 h prior to lysis and assayed for mitochondrial protein expression (n=3). 
 
 
Figure 3. Osteoblast mineralization following acute PVI stimulation. Alizarin red 
staining of osteoblasts treated with 0.35% PVI or PBS control was quantified at 
OD550nm using 10% cetyl pyridinium chloride. (n=8, **p<0.01).  
 
Figure Legends
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